Central role of TGF-β in the pathogenesis of diabetic nephropathy and macrovascular complications: A hypothesis

Diabetic Medicine

Volumn 13, Issue 4, 1996, Pages 313-320

  Yokoyama, H ^a,b   Deckert, T ^a  

^a STENO DIABETES CENTER   (Denmark)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerotic vascular disease; Extracellular matrix; IDDM; Nephropathy; Transforming growth factor

Indexed keywords

BIGLYCAN; COLLAGEN; DECORIN; FIBRONECTIN; HEPARIN; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA;

ARTERIOSCLEROSIS; COMPLICATION; DIABETIC NEPHROPATHY; ETIOLOGY; EXTRACELLULAR MATRIX; HUMAN; HYPOTHESIS; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; PATHOGENESIS; PROTEINURIA; REVIEW; RISK FACTOR; VASCULAR DISEASE;

ANIMALS; CYTOKINES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; HUMANS; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030012265     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199604)13:4<313::AID-DIA56>3.0.CO;2-7     Document Type: Review

References (89)

1. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985; 78: 785-793.
2. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T. Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diabetes 1987; 36: 205-209.
3. Yokoyama H, Uchigata Y, Otani T, Maruyama A, Aoki K, Omori Y, et al. Development of diabetic nephropathy in Japanese patients with IDDM. J Diab Comp 1994; 8: 7-12.
4. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin-dependent diabetes mellitus. Br Med J 1987; 294: 1651-1654.
5. Kofoed-Enevoldsen A, Jensen T, Botch-Johsen K, Deckert T. Incidence of retinopathy in type 1 diabetes: association with clinical nephropathy. J Diab Compl 1987; 3: 96-99.
6. Parving HH, Hommel E, Mathiesen E. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin-dependent diabetes. Br Med J 1988;296: 156-160.
7. Jensen T, Botch-Johsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987; 30: 144-148.
8. van den Born J, Berden JHM. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 1995; 38: 161-172.
9. Wakisaka M, Spiro MJ, Spiro RG. Synthesis of type IV collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes 1994; 43: 95-103.
10. Danne T, Spiro MJ, Spiro RG. Effect of high glucose on type IV collagen production by cultured glomerular epithelial, endothelial, and mesangial cells. Diabetes 1993; 42: 170-177.
11. Fukui M, Nakamura T, Eoihara I, Shirato I, Tomino Y, Koide H. ECM gene expression and its modulation by insulin in diabetic rats. Diabetes 1992; 41: 1520-1527.
12. Cagliero E, Roth T, Roy S, Lorenzi M. Characteristics and mechanisms of high-glucose-induced over-expression of basement membrane components in cultured human endothelial cells. Diabetes 1991; 40: 102-110.
13. Haneda M, Kikkawa R, Horide N, Togawa M, Koya D, Kajiwara N, et al. Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells. Diabetologia 1991; 34: 198-200.
14. Roy S, Sala R, Cagliero E, Lorenzi M. Over-expression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci 1990; 87: 404-408.
15. Ledbetter S, Copeland EJ, Noonan D, Vogeli G, Hassel J. Altered steady-state mRNA levels of basement membrane proteins in diabetic mouse kidneys and thromboxane synthase inhibition. Diabetes 1990; 39: 196-203.
16. Shimomura H, Spiro RG. Studies of macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 1987; 36; 374-381.
17. Tamsma JT, van den Born J, Bruijn JA, Assmann KJMA, Weening JJ, Berden JHM, et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulfate in the glomerular basement membrane. Diabetologia 1994; 37: 313-320.
18. Nerlich AG, Schleicher ED, Wiest I, Specks U. Immunohistochemical localization of collagen VI in diabetic glomeruli. Kidney Int 1994; 45: 1648-1656.
19. Makino H, Yamasaki Y, Haramoto T, Shikata K, Hironaka K, Ota Z, et al. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab Invest 1993; 68: 45-55.
20. Vernier RL, Steffes MW, Sisson-Ross S, Mauer M. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int 1992; 41: 1070-1080.
21. Woodrow D, Moss J, Shore I, Spiro RG. Diabetic glomerulosclerosis - immunogold ultrastructural studies on the glomerular distribution of type IV collagen and heparan sulfate proteoglycan. J Pathol 1992; 167: 49-58.
22. Nerlich AG, Schleicher ED. Immunohistochemical localization of extracellular matrix in human diabetic glomerular lesions. Am J Pathol 1991; 139: 889-899.
23. Rohrbach R. Reduced content and abnormal distribution of anionic sites (acid proteoglycans) in the diabetic glomerular basement membrane. Virchows A 1986; 51: 127-135.
24. Deckert T, Jensen T, Feldt-Rasmussen B, Kofoed-Enevoldsen A, Borch-Johnsen K, Stender S. Albuminuria a risk marker of atherosclerosis in insulin dependent diabetes mellitus. Cardiovasc Risk Factors 1991; 1: 347-360.
25. Williamson JR, Tilton RG, Chang K, Kilo C. Basement membrane abnormalities in diabetes mellitus. Relationship to clinical microangiopathy. Diabetes Metab Rev 1988; 4: 339-370.
26. Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 1993; 36: 316-322.
27. Dybdahl H, Ledet T. Diabetic macroangiopathy. Quantitative histopathological studies of the extramural coronary arteries from type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1987; 30: 882-886.
28. Feldt-Rasmussen B. Increased transcapillary rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1986; 29: 282-286.
29. Border WA, Noble NA. Transforming growth factor b in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
30. Derynck R, Jarrett JA, Chen D, Eaton H, Bell JR, Assoian K, et al. Human transforming growth factor β cDNA sequence and expression in tumor cell lines. Nature (Lond) 1985; 316: 701.
31. Ando T, Okuda S, Tamaki K, Yoshitomi K, Fujishima M. Localization of transforming growth factor-β and latent transforming growth factor-β binding protein in rat kidney. Kidney Int 1995; 47: 733-739.
32. Massague J. Receptors for the TGF-β family. Cell 1992; 69: 1067-1070.
33. Lopez-Casillas F, Cheifez S, Doody J, Andres L, Lane WS, Massague J. Betaglycan presents ligand to the TGF-β signaling receptor. Cell 1993; 73: 1435-1444.
34. Kim SJ, Angel P, Lafyatis R, Roberts AB. Autoinduction of transforming growth factor β1 is mediated by the AP-1 complex. Mol Cell Biol 1990; 10: 1492-1497.
35. Ignotz RA, Massague J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261: 4337-4345.
36. Bassols A, Massague J. Transforming growth factor β regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J Biol Chem 1988; 263: 3039-3045.
37. Edwards DR, Murphy C, Reynolds J, Whitham SE, Docherty JP, Angel P, et al. Transforming growth factor β modulates the expression of collagenase and metalloproteinase inhibitor. Euro Mol Biol Organ J 1987; 6: 1899-1904.
38. Laiho M, Sakela O, Keski-Oja J. Transforming growth factor-β induction of type-1 plasminogen activator inhibitor. J Biol Chem 1987; 262: 17467-17474.
39. Ignotz RA, Massegue J. Cell adhesion protein as targets for transforming growth factor β action. Cell 1987; 51: 189-197.
40. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Supression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990; 346: 371-374.
41. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. Possible role in expression of the mesangial extracellular matrix. J Clin Invest 1990; 86: 453-462.
42. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene in the rat kidney. J Clin Invest 1993; 92: 2597-2601.
43. Wolf C, Sharma K, Chen Y, Ericksen M, Ziyadeh F. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 1992; 42: 647-656.
44. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-1818.
45. Bollineni JS, Reddi AS. Transforming growth factor-β1 enhances glomerular collagen synthesis in diabetic rats. Diabetes 1993; 42: 1673-1677.
46. Nakamura T, Fukui M, Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993; 42: 450-456.
47. Shankland SJ, Scholey JW. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int 1994; 46: 430-442.
48. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994; 93: 536-542.
49. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380.
50. Parving H-H, Viberti GC, Keen H, Christiansen JS, Lassen NA. Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 1983; 32: 943-949.
51. Zats R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner B. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
52. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 34: F477-F486.
53. Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, Narins RG. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 1992; 90: 1932-1943.
54. Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40: 583-596.
55. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993; 3: 1531-1540.
56. Anderson PW, Do YS, Hsueh WA: Angiotensin II causes mesangial cell hypertrophy. Hypertension 1993; 21: 29-35.
57. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
58. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biological basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
59. Schmidt AM, Hori O, Brett J, Yan DS, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implication for induction of oxidant stress and cellular dysfuction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14: 1521-1528.
60. Makita Z, Biccala R, Rayfield EJ, Kaufman AM, Korbert SM, Barth RH. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet 1994; 343: 1519-1522.
61. Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 1993; 92: 212-217.
62. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 1991; 174: 931-939.
63. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci 1992; 89: 2873-2877.
64. Pankewycz OG, Guan JX, Bolton WK, Gomez A, Benedict JF. Renal TGF-β regulation in spontaneously diabetic NOD mice with correlations in mesangial cells. Kidney Int 1994; 46: 748-758.
65. Kasinath BS. Glomerular endothelial cell proteoglycans - regulation by TGF-β1. Arch Bio Biophys 1993; 305: 370-377.
66. Nakamura T, Miller D, Ruoslahti E, Border W. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β1. Kidney Int 1992; 41: 1213-1221.
67. Border WA, Okuda S, Languino LR, Ruoslahti E. Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int 1990; 37: 689-695
68. Nakamura T, Fukui M, Ebihara I, Yasuhiko T, Koide H, et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993; 42:450-456.
69. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995;48:111-117.
70. Majeski MW, Linder V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor β1 during arterial injury. J Clin Invest 1991; 88: 904-910.
71. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-β1 supress intimal hyperplasia in a rat model. J Clin Invest 1994; 93: 1172-1178.
72. Ferns GA, Raines EW, Sprugel H, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 245: 1129-1132.
73. Edelman ER, Nugent MA, Smith LT, Karnovsky MJ. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest 1992; 89: 465-473.
74. LeNoble FA, Hekking JW, VanStraaten HW, Slaaf DW, Struyker-Boudier HA. Angiotensin II stimulates angiogenesis in the chorioallantoic membrane of the chick embryo. Eur J Pharmacol 1991; 195: 305-306.
75. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62: 749-756.
76. Daemen MJ, Lonbardi DM, Dosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450-456.
77. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia. Autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-461.
78. Koibuchi Y, Lee WS, Gibbons GH, Pratt R. Role of transforming growth factor-β1 in the cellular growth response to angiotensin II. Hypertension 1993; 21: 1046-1050.
79. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-β underlies development of progressive kidney fibrosis. Kidney Int 1994; 45: 916-927.
80. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361-364.
81. Lopez-Casillas F, Payne HM, Andres JL, Massague J. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. Cell 1994; 124: 557-568.
82. Floege J, Eng E, Young BA, Couser WG, Johnseon RJ. Heparin surpresses mesangial cell proliferation and matrix expansion in experimental mesangioproliterative glomerulonephritis. Kidney Int 1993; 43: 369-380.
83. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Baggio B. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992; 42: 285-291.
84. Gambaro G, Venturuni AP, Noonan DM, Fries W, Baggio B. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994; 46: 797-806.
85. Myrup B, Hansen PM, Jensen T, Kofoed-Enevoldsen A, Feldt-Rasmussen B, Gram J, et al. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 1995; 345: 421-422.
86. Yokoyama H, Myrup B, Oturai P, Deckert T. Heparin, a possible therapy for diabetic complications: The effect on mesangial and myomedial cells in vivo and in vitro, especially with relation to extracellular matrix. J Diab Comp 1995; 9: 97-103.
87. Snow AD, Bolender RP, Wight TN, Clowes AW. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 1990; 137: 313-330.
88. Clows AW, Clowes MM, Vergel SC, Muller RKM, Baumgarter HR. Heparin and cilazapril together inhibit injury-induced intimal hyperplasia. Hypertension 1991; 18 (suppl II): 65-69.
89. Silber IE, Walenga JM, Fareed J, Kovacs EJ. Heparan sulphate inhibition of cell proliferation induced by TGFβ and PDGF. Mediators of inflammation 1993; 2: 299-302.